Treatment Attrition, Concomitant Pharmaceutical Use, Temporal Claims-Based Utilization, and Real-World Characteristics Among Esketamine New Initiators in the United States, 2019-2022
Brandon G. Truax preprint
ABSTRACT Aims To investigate real-world treatment attrition, concomitant use of pharmaceuticals with known drug-interactions, total cost of care, claims-based outcomes, and health disparities for individuals initiated on esketamine therapy in the United States. Methods Individuals aged 18-64 with >=1 adjudicated claim for esketamine intranasal spray from 2019 to 2022 in the Optum Labs Data...